Bayer Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Bayer ha aumentado sus beneficios a una tasa media anual de 14.5%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento anual de 10.5%. Los ingresos han ido creciendo a una tasa media de 4.6% al año.

Información clave

14.5%

Tasa de crecimiento de los beneficios

14.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	7.3%
Tasa de crecimiento de los ingresos	4.6%
Rentabilidad financiera	-8.9%
Margen neto	-6.2%
Próxima actualización de resultados	14 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Aug 05

Is Bayer (ETR:BAYN) A Risky Investment?

Jun 28

Bayer (ETR:BAYN) Use Of Debt Could Be Considered Risky

Dec 07

Is Bayer (ETR:BAYN) A Risky Investment?

Aug 18

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Bayer. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

XTRA:BAYN Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	47,637	-2,941	14,714	5,835
30 Sep 23	47,775	-3,667	14,881	5,511
30 Jun 23	48,714	1,448	15,565	6,175
31 Mar 23	50,489	3,037	16,143	6,285
31 Dec 22	50,739	4,150	16,036	6,168
30 Sep 22	49,857	4,700	15,993	5,884
30 Jun 22	48,357	4,239	15,413	5,681
31 Mar 22	46,392	2,202	14,936	5,582
31 Dec 21	44,081	1,000	14,531	5,326
30 Sep 21	42,958	222	12,479	3,449
30 Jun 21	41,683	-7,565	13,772	5,010
31 Mar 21	40,883	-14,849	13,524	4,780
31 Dec 20	41,400	-15,569	13,886	4,884
30 Sep 20	42,155	-15,995	15,174	7,215
30 Jun 20	43,479	-7,303	13,820	5,100
31 Mar 20	44,138	2,631	14,594	5,267
31 Dec 19	43,545	2,391	14,801	5,282
30 Sep 19	43,150	-1,530	15,360	5,196
30 Jun 19	42,581	287	15,241	5,082
31 Mar 19	39,856	557	14,366	4,978
31 Dec 18	36,742	1,374	13,238	4,701
30 Sep 18	34,983	6,027	13,276	4,525
30 Jun 18	33,747	3,237	12,480	4,434
31 Mar 18	34,473	3,486	12,579	4,254
31 Dec 17	35,015	3,249	12,689	4,272
30 Sep 17	35,242	3,087	12,878	4,381
30 Jun 17	35,475	3,924	12,949	4,347
31 Mar 17	32,769	3,991	12,448	4,305
31 Dec 16	34,943	3,743	12,686	4,321
30 Sep 16	37,405	3,837	12,959	4,299
30 Jun 16	40,151	3,971	13,327	4,291
31 Mar 16	46,146	4,210	14,110	4,339
31 Dec 15	46,085	4,025	14,250	4,207
30 Sep 15	45,592	3,616	14,145	4,020
30 Jun 15	44,555	3,429	13,796	3,852
31 Mar 15	42,780	3,206	13,144	3,665
31 Dec 14	41,339	3,326	12,576	3,535
30 Sep 14	40,435	3,569	11,878	3,642
30 Jun 14	40,111	3,501	11,898	3,558
31 Mar 14	40,243	3,425	12,131	3,495
31 Dec 13	40,157	3,189	12,195	3,407
30 Sep 13	40,129	3,100	12,513	3,104
30 Jun 13	40,147	2,883	12,493	3,063

Ingresos de calidad: BAYN actualmente no es rentable.

Margen de beneficios creciente: BAYN actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: BAYN no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 14.5% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de BAYN en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: BAYN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (4%).

Rentabilidad financiera

Alta ROE: BAYN tiene una rentabilidad financiera negativa (-8.89%), ya que actualmente no es rentable.

Bayer Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Recent updates

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Price target decreased by 7.7% to €42.48

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?

Williams Hart & Boundas Wins Against Bayer

Price target decreased by 7.7% to €51.57

Price target decreased by 7.6% to €57.57

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 13%

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

Consensus EPS estimates fall by 11%

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Consensus EPS estimates fall by 12%

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 24%

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

Is Bayer (ETR:BAYN) A Risky Investment?

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of €2.40 per share at 4.0% yield

Consensus EPS estimates fall by 10%

Full year 2022 earnings: EPS misses analyst expectations

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Blackford Analysis Ltd.

Bayer AG Announces CEO Changes

Inclusive Capital Partners Provides Information to Shareholders of Bayer Aktiengesellschaft

Union Investment Criticizes Bayer AG Chairman for Lack of Engagement

Bayer Aktiengesellschaft (XTRA:BAYN) agreed to acquire Blackford Analysis Ltd.

Bayer Aktiengesellschaft to Report Q2, 2023 Results on Aug 08, 2023

Bayer (ETR:BAYN) Use Of Debt Could Be Considered Risky

Afrin WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays

Bayer Aktiengesellschaft (XTRA:BAYN) acquired Targenomix GmbH.

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Bayer Aktiengesellschaft Extends Development Program for Investigational Product Elinzanetant with Phase III Study in Breast Cancer Patients with Vasomotor Symptoms Caused by Endocrine Therapy

Bayer to Highlight Additional Analyses From Comprehensive KERENDIA® (finerenone) Clinical Trial Program at the American Society of Nephrology’s 2022 Kidney Week

Cinven Limited completed the acquisition of Environmental Science Professional business from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data from Innovative Science At ESMO Congress 2022

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA® (finerenone) and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian

Is Bayer (ETR:BAYN) A Risky Investment?

Bayer Launches ForGround

U.S. FDA Approves Bayer's Additional Indication of NUBEQA (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Bayer Aktiengesellschaft (XTRA:BAYN) signed a shareholders agreement to acquire 65% stake in CoverCress Inc. from Bunge Ventures and Chevron U.S.A. Inc.

Desglose de ingresos y gastosBeta

Desglose de ingresos y gastos
Beta